Awardee OrganizationSCRIPPS RESEARCH INSTITUTE, THE
Description
Abstract Text
DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) infection is a worldwide health problem. It is estimated that there are 200 to 500 million HBV chronic carriers in the world for whom, to date, there is no reliable treatment. HBV causes both acute and chronic liver disease and the estimated relative risk of primary hepatocellular carcinoma (PHC) in chronic HBV carriers is approximately 100 times greater than in uninfected individuals. Therefore, effective treatments for chronic HBV infection are required. In these studies, the mechanism(s) regulating the initial steps in the synthesis of hepatitis B virus (HBV) DNA will be investigated. HBV DNA synthesis is initiated by binding of the viral polymerase to a stem-loop structure, epsilon, located at the 5'-end of the HBV pregenomic RNA. Initially, the first three nucleotides of HBV minus-strand DNA are synthesized utilizing the amino-terminal domain of the polymerase as a primer and the bulge region of epsilon as a template. The HBV polymerase with the covalently attached trinucleotide sequence is subsequently translocated to the DR1 sequence at the 3'-end of the pregenomic RNA. HBV minus-strand DNA synthesis then proceeds by the reverse transcription of the pregenomic RNA. The mechanism(s) regulating the translocation step are unknown. Recently, a regulatory sequence element, phi, located immediately upstream of the DR1 sequence at the 3'-end of the pregnomic RNA that is important for efficient viral replication and is complementary to the 5'-half of epsilon was identified. This finding suggests that the translocation of the minus-strand primer from epsilon to DR1 might be mediated by a conformational change in the pregenomic RNA that brings the primer into proximity with the DR1 sequence at the 3'-end of the pregenomic RNA. The conservation of the complementarity between epsilon and phi in the woodchuck hepatitis virus (WHV) and the duck hepatitis B virus (DHBV) genomes also supports this contention. Therefore, the role of the complementarity between epsilon and phi in regulating HBV replication will be examined directly by mutational analysis of these sequence elements. This approach is aimed at identifying possible targets for therapeutic intervention in chronic HBV infection.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
781613492
UEI
PHZJFZ32NKH4
Project Start Date
15-July-2003
Project End Date
30-June-2005
Budget Start Date
01-July-2004
Budget End Date
30-June-2005
Project Funding Information for 2004
Total Funding
$93,850
Direct Costs
$50,000
Indirect Costs
$43,850
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Allergy and Infectious Diseases
$93,850
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R03AI055584-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R03AI055584-02
Patents
No Patents information available for 5R03AI055584-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R03AI055584-02
Clinical Studies
No Clinical Studies information available for 5R03AI055584-02
News and More
Related News Releases
No news release information available for 5R03AI055584-02
History
No Historical information available for 5R03AI055584-02
Similar Projects
No Similar Projects information available for 5R03AI055584-02